First Time Loading...

Medigene AG
XETRA:MDG1

Watchlist Manager
Medigene AG Logo
Medigene AG
XETRA:MDG1
Watchlist
Price: 1.44 EUR Market Closed
Updated: May 12, 2024

Intrinsic Value

MDG1's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. [ Read More ]

The intrinsic value of one MDG1 stock under the Base Case scenario is 4.21 EUR. Compared to the current market price of 1.44 EUR, Medigene AG is Undervalued by 66%.

Key Points:
MDG1 Intrinsic Value
Base Case
4.21 EUR
Undervaluation 66%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Medigene AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MDG1 stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Medigene AG

Provide an overview of the primary business activities
of Medigene AG.

What unique competitive advantages
does Medigene AG hold over its rivals?

What risks and challenges
does Medigene AG face in the near future?

Summarize the latest earnings call
of Medigene AG.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Medigene AG.

Provide P/S
for Medigene AG.

Provide P/E
for Medigene AG.

Provide P/OCF
for Medigene AG.

Provide P/FCFE
for Medigene AG.

Provide P/B
for Medigene AG.

Provide EV/S
for Medigene AG.

Provide EV/GP
for Medigene AG.

Provide EV/EBITDA
for Medigene AG.

Provide EV/EBIT
for Medigene AG.

Provide EV/OCF
for Medigene AG.

Provide EV/FCFF
for Medigene AG.

Provide EV/IC
for Medigene AG.

Show me price targets
for Medigene AG made by professional analysts.

What are the Revenue projections
for Medigene AG?

How accurate were the past Revenue estimates
for Medigene AG?

What are the Net Income projections
for Medigene AG?

How accurate were the past Net Income estimates
for Medigene AG?

What are the EPS projections
for Medigene AG?

How accurate were the past EPS estimates
for Medigene AG?

What are the EBIT projections
for Medigene AG?

How accurate were the past EBIT estimates
for Medigene AG?

Compare the revenue forecasts
for Medigene AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Medigene AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Medigene AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Medigene AG compared to its peers.

Compare the P/E ratios
of Medigene AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Medigene AG with its peers.

Analyze the financial leverage
of Medigene AG compared to its main competitors.

Show all profitability ratios
for Medigene AG.

Provide ROE
for Medigene AG.

Provide ROA
for Medigene AG.

Provide ROIC
for Medigene AG.

Provide ROCE
for Medigene AG.

Provide Gross Margin
for Medigene AG.

Provide Operating Margin
for Medigene AG.

Provide Net Margin
for Medigene AG.

Provide FCF Margin
for Medigene AG.

Show all solvency ratios
for Medigene AG.

Provide D/E Ratio
for Medigene AG.

Provide D/A Ratio
for Medigene AG.

Provide Interest Coverage Ratio
for Medigene AG.

Provide Altman Z-Score Ratio
for Medigene AG.

Provide Quick Ratio
for Medigene AG.

Provide Current Ratio
for Medigene AG.

Provide Cash Ratio
for Medigene AG.

What is the historical Revenue growth
over the last 5 years for Medigene AG?

What is the historical Net Income growth
over the last 5 years for Medigene AG?

What is the current Free Cash Flow
of Medigene AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Medigene AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Medigene AG

Current Assets 12.4m
Cash & Short-Term Investments 12.4m
Efficiency

Earnings Waterfall
Medigene AG

Revenue
4.6m EUR
Operating Expenses
-8.9m EUR
Operating Income
-4.3m EUR
Other Expenses
58k EUR
Net Income
-4.3m EUR

Free Cash Flow Analysis
Medigene AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

MDG1 Profitability Score
Profitability Due Diligence

Medigene AG's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Positive 3-Years Revenue Growth
Low 3-Year Average ROE
38/100
Profitability
Score

Medigene AG's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

MDG1 Solvency Score
Solvency Due Diligence

Medigene AG's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Low Interest Coverage
38/100
Solvency
Score

Medigene AG's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MDG1 Price Targets Summary
Medigene AG

Wall Street analysts forecast MDG1 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MDG1 is 2.67 EUR with a low forecast of 2.25 EUR and a high forecast of 3.15 EUR.

Lowest
Price Target
2.25 EUR
57% Upside
Average
Price Target
2.67 EUR
85% Upside
Highest
Price Target
3.15 EUR
119% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

MDG1 Price
Medigene AG

1M 1M
-30%
6M 6M
-15%
1Y 1Y
-14%
3Y 3Y
-64%
5Y 5Y
-83%
10Y 10Y
-72%
Annual Price Range
1.44
52w Low
1.38
52w High
2.72
Price Metrics
Average Annual Return -28.88%
Standard Deviation of Annual Returns 15.18%
Max Drawdown -84%
Shares Statistics
Market Capitalization 42.4m EUR
Shares Outstanding 29 475 200
Percentage of Shares Shorted
N/A

MDG1 Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Medigene AG Logo
Medigene AG

Country

Germany

Industry

Biotechnology

Market Cap

42.4m EUR

Dividend Yield

0%

Description

MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. The company is headquartered in Planegg, Bayern and currently employs 121 full-time employees. The company went IPO on 2000-06-30. The firm focuses on the development of personalized T cell-based immunotherapies. The company develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The firm operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.

Contact

BAYERN
Planegg
Lochhamer Strasse 11
+49892000330.0
https://www.medigene.de/

IPO

2000-06-30

Employees

121

Officers

CEO & Member of Executive Management Board
Dr. Selwyn Ho MB BS, MBBS
Chief Scientific Officer, Member of Executive Management Board and Head of Research & Development
Dr. Dolores J. Schendel
Co-Founder & Chairman Scientific Advisory Board
Dr. Ernst-Ludwig Winnacker
Chief Financial Officer
Dr. Birger Kohlert
Vice President of Investor Relations & Corporate Communications
Pamela Keck
VP and Head of Clinical Research & Development
Dr. Kirsty Crame M.D.

See Also

Discover More
What is the Intrinsic Value of one MDG1 stock?

The intrinsic value of one MDG1 stock under the Base Case scenario is 4.21 EUR.

Is MDG1 stock undervalued or overvalued?

Compared to the current market price of 1.44 EUR, Medigene AG is Undervalued by 66%.